Suppr超能文献

运用网络药理学和分子对接技术阐明恒清Ⅱ号方治疗阿尔茨海默病的作用机制。

Elucidating the therapeutic mechanism of Hengqing II decoction in Alzheimer's disease using network pharmacology and molecular docking techniques.

作者信息

Wang Yajing, Jiang Jiahui, Chen Shuyu, Chen Qian, Yan Xiaojing, Shen Xiaozhong

机构信息

Department of Pharmacy, Changzhou University. Changzhou, PR China.

Changzhou Key Laboratory of Human Use Experience Research & Transformation of Menghe Medical School, Changzhou Hospital affiliated to Nanjing University of Chinese Medicine, Changzhou, PR China.

出版信息

Fitoterapia. 2024 Apr;174:105860. doi: 10.1016/j.fitote.2024.105860. Epub 2024 Feb 15.

Abstract

PURPOSE

The aim of our research was to investigate the mechanism of the Hengqing II decoction in treating Alzheimer's disease (AD) through network pharmacology and experimental validation methods.

METHODS

Firstly, the major chemical compounds of Hengqing II decoction were characterized by ultra-high-performance liquid chromatography-high resolution mass spectrometry (UHPLC-Q-TOF-MS/MS), and the gene sets related to AD treatment by Hengqing II decoction were collected through the database of PubChem, Swiss TargetPrediction, and DisGeNET. Secondly, a multi-level molecular network of "Traditional Chinese medicine (TCM)-compound-target-disease" was constructed and visualized using the STRING platform and Cytoscape 3.9.1 software, and the enrichment analysis based on the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway databases was performed to predict the potential active compounds and targets of Hengqing II decoction for treating AD. Finally, molecular docking simulation was applied to investigate the binding interactions between potential active compounds and key targets, and the western blotting technique was employed to examine the expression levels of AKT1, TNF-α, and NOS2 proteins affected by active compounds.

RESULTS

Totally 120 compounds in Hengqing II decoction were characterized by UHPLC-Q-TOF-MS/MS. Network pharmacology results showed that potential active compounds in Hengqing II decoction in treating AD included catalpol, gastrodin, and rehmannioside D, etc., and the main target proteins were TNF-α, NOS2, and AKT1. Further functional enrichment analysis revealed that Hengqing II decoction mainly exerted its therapeutic effects on AD by regulating lipid and atherosclerosis signaling pathways, AD signaling pathways, AKT1 signaling pathways, and PTGS2 signaling pathways.

CONCLUSION

Hengqing II decoction exerted therapeutic effects on AD through multi-component, multi-target, and multi-pathway regulation, and its action mechanisms were related to oxidative stress, neuroinflammation, autophagy, and other pathways. Our research laid the data foundation for further exploration of action mechanism and clarification of clinical positioning and provided new ideas and clues in TCM formula research.

摘要

目的

本研究旨在通过网络药理学和实验验证方法,探讨恒清Ⅱ号方治疗阿尔茨海默病(AD)的作用机制。

方法

首先,采用超高效液相色谱-高分辨质谱(UHPLC-Q-TOF-MS/MS)对恒清Ⅱ号方的主要化学成分进行表征,并通过PubChem、Swiss TargetPrediction和DisGeNET数据库收集与恒清Ⅱ号方治疗AD相关的基因集。其次,利用STRING平台和Cytoscape 3.9.1软件构建并可视化“中药-化合物-靶点-疾病”多层次分子网络,并基于基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路数据库进行富集分析,预测恒清Ⅱ号方治疗AD的潜在活性化合物和靶点。最后,应用分子对接模拟研究潜在活性化合物与关键靶点之间的结合相互作用,并采用蛋白质免疫印迹技术检测活性化合物对AKT1、TNF-α和NOS2蛋白表达水平的影响。

结果

通过UHPLC-Q-TOF-MS/MS共鉴定出恒清Ⅱ号方中的120种化合物。网络药理学结果显示,恒清Ⅱ号方治疗AD的潜在活性化合物包括梓醇、天麻素和地黄苷D等,主要靶蛋白为TNF-α、NOS2和AKT1。进一步的功能富集分析表明,恒清Ⅱ号方主要通过调节脂质与动脉粥样硬化信号通路、AD信号通路、AKT1信号通路和PTGS2信号通路发挥对AD的治疗作用。

结论

恒清Ⅱ号方通过多成分、多靶点、多途径调节发挥对AD的治疗作用,其作用机制与氧化应激、神经炎症、自噬等途径相关。本研究为进一步探索其作用机制、明确临床定位奠定了数据基础,为中药方剂研究提供了新的思路和线索。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验